{"id":"NCT00419393","sponsor":"UCB Pharma","briefTitle":"Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures","officialTitle":"An Open-label, Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Treatment of Partial-onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2010-03","completion":"2010-03","firstPosted":"2007-01-08","resultsPosted":"2011-07-13","lastUpdate":"2014-09-05"},"enrollment":190,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Keppra XR (Levetiracetam XR)","otherNames":["Keppra XR"]}],"arms":[{"label":"Keppra XR (Levetiracetam XR)","type":"EXPERIMENTAL"}],"summary":"To provide continued treatment of Keppra XR (Levetiracetam XR) and to assess the long term safety of Keppra XR in subjects with partial onset seizures.","primaryOutcome":{"measure":"Number of Subjects Who Experienced at Least 1 Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years)","timeFrame":"Duration of the Treatment Period (6 months-2 years)","effectByArm":[{"arm":"Keppra XR","deltaMin":126,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":35,"countries":["United States","Mexico","Poland","Russia"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":189},"commonTop":["Headache","Nasopharyngitis","Somnolence","Influenza","Dizziness"]}}